Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Multicenter Randomized Trial Evaluating in Patients At the Time of the Primary HIV-1 Infection, the Impact on the Viral Reservoir of a Combination Including Tenofovir/emtricitabine and Dolutegravir or Tenofovir/emtricitabine and Darunavir/cobicistat

Next Previous
Trial Profile

Phase III Multicenter Randomized Trial Evaluating in Patients At the Time of the Primary HIV-1 Infection, the Impact on the Viral Reservoir of a Combination Including Tenofovir/emtricitabine and Dolutegravir or Tenofovir/emtricitabine and Darunavir/cobicistat

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 28 Jun 2022 Results published in the Journal of Antimicrobial Chemotherapy
  • 23 Feb 2022 Results of a sub-study to compare the kinetics of HIV-RNA and total HIV-DNA in the genital compartment in subjects receiving either tenofovir/emtricitabine/dolutegravir or tenofovir/emtricitabine/darunavir/cobicistat as a first-line combined ART (cART) at the time of PHI, published in the Journal of Antimicrobial Chemotherapy
  • 21 Jul 2021 Primary endpoint (HIV-DNA levels in the peripheral blood mononuclear cell (PBMC) at week 48) has been met, according to Results presented at the 11th International AIDS Society Conference on HIV Science.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top